Coastal Infusion Administers Crysvita®

Crysvita (burosumab-twza) is used to treat X-linked hypophosphatemia (XLH). XLH is a rare genetic disorder where the kidneys excrete too much phosphate into the urine, leading to low levels of phosphate in the blood. This results in impaired bone mineralization and can cause skeletal abnormalities. Patients with X-linked hypophosphatasemia or tumor-induced osteomalacia have abnormally high levels of FGF23, which causes the kidneys to stop returning phosphate into the bloodstream.

Crysvita is a monoclonal antibody designed to recognize and attach to the FGF23 protein. By attaching to the FGF23 protein, Crysvita blocks its activity, allowing the kidneys to return phosphate and restore normal levels of phosphate in the blood.

What It Treats

Crysvita is used to threat X-linked hypophosphatemia (XLH).

Prescribed By

Crysvita is most often prescribed by Endocrinologists and Nephrologists.

How it’s Administered

Crysvita is administered by subcutaneous injection. Crysvita injections take only a few minutes.

Frequency

Crysvita is generally administered every four weeks.

Additional Resources

• Crysvita Website
• Prescribing Information
• Co-Pay Assistance

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies